-
Our Vision is to improve healthcare as a global provider of innovative and reliable diagnostic tests. -
Our Mission is to identify and develop novel patentable diagnostic markers and technologies which can be commercialised to meet clinical needs, both in the laboratory and at the point of care. -
We will collaborate with partners, create branded products and identify complementary businesses which support our objective of continuing to grow as a respected and profitable healthcare company. -
Our Values include meeting all current and future regulatory, quality and environmental standards appropriate for our industry and the countries in which we operate.
Executive Directors
 |
Erling M H Sundrehagen MD, MSc, PhD Erling is a medical doctor, a Master of Science in nuclear chemistry and has a PhD in immunology. Erling founded Axis Biochemicals ASA in 1985 and was appointed to the Board of Axis-Shield when Axis Biochemicals ASA merged with Shield Diagnostics in 1999. Erling has over thirty years of experience within clinical chemistry and biochemistry. He has received various international awards for his research in clinical chemistry and is experienced in international patenting. |
Axis-Shield Directors and Senior Management
 |
John Brown PhD MBA FRSE Non-Executive Chairman |
|
|
Erling M H Sundrehagen MD, MSc, PhD Chief Scientific Officer |
 |
David Bond CA Group Financial Controller |
 |
Kjersti Grimsrud MSc, Biotechnology Managing Director, Point-of-Care Division |
 |
Colin King MBA Site Director, Laboratory Division |
 |
George Zajicek BPharm, |
